Company news

AstraZeneca PLC news in 2020

AstraZeneca PLC's news releases, calls and decks from 2020, newest first.

View company

EMTN Programme Routine Technical Update

June 11, 2020

Lynparza EU CHMP opinion in pancreatic cancer

June 1, 2020

Brilinta obtains additional US approval

June 1, 2020

Imfinzi sustained overall survival in CASPIAN

May 29, 2020

Enhertu DESTINY-Gastric01 results from ASCO 2020

May 29, 2020

Tagrisso unprecedented adjuvant lung cancer data

May 29, 2020

Enhertu US orphan designation in gastric cancer

May 22, 2020

AstraZeneca advances response to COVID-19 outbreak

May 21, 2020

Lynparza approved in the US for prostate cancer

May 20, 2020

Enhertu US Breakthrough status for lung cancer

May 18, 2020

Bevespi Aerosphere approved in China for COPD

May 18, 2020

Lynparza gets broader US ovarian cancer approval

May 11, 2020

Enhertu designated gastric cancer BTD

May 11, 2020

Brazikumab rights recovered by AstraZeneca

May 11, 2020

Farxiga approved by FDA for heart failure (HFrEF)

May 6, 2020

AZN: first-quarter 2020 results

April 29, 2020

Lynparza shows overall survival in prostate cancer

April 24, 2020

Changes to arrangements for AGM

April 17, 2020

Tagrisso adjuvant trial overwhelmingly positive

April 14, 2020

Koselugo (selumetinib) approved in the US for NF1

April 14, 2020

AstraZeneca divestment of Movantik completed

April 2, 2020

Imfinzi approved in US for small cell lung cancer

March 30, 2020

Farxiga CKD trial early stop for positive efficacy

March 30, 2020

Lokelma approved in Japan for hyperkalaemia

March 26, 2020

Lynparza granted orphan drug designation in Japan

March 19, 2020

Imfinzi confirmed overall survival in CASPIAN

March 17, 2020

Update on Phase III GY004 trial for cediranib

March 12, 2020

Update on Phase III DANUBE trial in bladder cancer

March 6, 2020

Divestment of hypertension medicines completed

March 2, 2020

AstraZeneca divests global rights to Movantik

February 25, 2020

AZN: Full-year and Q4 2019 results

February 14, 2020

Enhertu Phase II trial met primary endpoint

January 27, 2020

Brilinta met primary endpoint in stroke trial

January 27, 2020

AstraZeneca to recover brazikumab (MEDI2070)

January 27, 2020

AstraZeneca divests hypertension medicines

January 27, 2020

Imfinzi, tremelimumab granted ODD in liver cancer

January 20, 2020

FDA grants Lynparza Priority Review for PROfound

January 20, 2020

Lynparza granted FDA Priority Review for PAOLA-1

January 13, 2020

Update on Epanova Phase III STRENGTH trial

January 13, 2020

Farxiga granted FDA heart failure Priority Review

January 6, 2020

Lokelma approved in China for hyperkalaemia

January 6, 2020

← Newer news releases

Decks in 2020